mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease
- 1 January 2011
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 300 (1) , F236-F244
Abstract
Rapamycin slows disease progression in the male Han:SPRD (Cy/+) rat with polycystic kidney disease (PKD). The aim of this study was to determine the effect of rapamycin on PKD and the relative contributions of the proproliferative mammalian target of rapamycin complexes 1 and 2 (mTORC1 and mTORC2) in female Cy/+ rats. Female Cy/+ rats were treated with rapamycin from 4 to 12 wk of age. In vehicle-treated Cy/+ rats, kidney volume increased by 40% and cyst volume density (CVD) was 19%. Phosphorylated S6 (p-S6) ribosomal protein, a marker of mTORC1 activity, was increased in Cy/+ rats compared with normal littermate controls (+/+) and decreased by rapamycin. Despite activation of mTORC1 in female Cy/+ rats, rapamycin had no effect on kidney size, CVD, number of PCNA-positive cystic tubular cells, caspase-3 activity, or the number of terminal deoxynucleotidyl transferase dUTP-mediated nick-end label-positive apoptotic cells. To determine a reason for the lack of effect of rapamycin, we studied the mTORC2 signaling pathway. On immunoblot of kidney, phosphorylated (Ser473) Akt (p-Akt), a marker of mTORC2 activity, was increased in female Cy/+ rats treated with rapamycin. Phosphorylated (Ser657) PKCα, a substrate of mTORC2, was unaffected by rapamycin in females. In contrast, in male rats, where rapamycin significantly decreases PKD, p-Akt (Ser473) was decreased by rapamcyin. PKCα (Ser657) was increased in male Cy/+ rats but was unaffected by rapamycin. In summary, in female Cy/+ rats, rapamycin had no effect on PKD and proproliferative p-Akt (Ser473) activity was increased by rapamycin. There were differential effects of rapamycin on mTORC2 signaling in female vs. male Cy/+ rats.Keywords
This publication has 39 references indexed in Scilit:
- Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1Molecular and Cellular Biology, 2009
- Emerging evidence of a link between the polycystins and the mTOR pathwaysPathoGenetics, 2009
- Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD)Nephrology Dialysis Transplantation, 2009
- Everolimus Retards Cyst Growth and Preserves Kidney Function in a Rodent Model for Polycystic Kidney DiseaseKidney and Blood Pressure Research, 2007
- Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AMLBlood, 2006
- Gender hormones and the progression of experimental polycystic kidney diseaseKidney International, 2005
- New insights into the molecular pathophysiology of polycystic kidney diseaseKidney International, 1999
- Characterization of the Han:SPRD rat model for hereditary polycystic kidney diseaseKidney International, 1994
- Autosomal-dominant polycystic kidney disease in the ratKidney International, 1993
- c-myc as an inducer of polycystic kidney disease in transgenic miceKidney International, 1991